 |
Buthionine sulfoxamine |
|---|---|
| Trade Name | |
| Orphan Indication | Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors |
| USA Market Approval | USA |
| USA Designation Date | 2005-10-05 00:00:00 |
| Sponsor | USC-CHLA Institute for Pediatric Clinical Research;Childrens Hospital of Los Angeles, 4650 Sunset Blvd, MS 55;Los Angeles, California, 90027 |
